Impact of time to treatment on visual outcomes in optic neuritis

Lesen Sie diesen Artikel auf Deutsch.

Takeaway

  • High-dose intravenous methylprednisolone (IVMP) treatment for optic neuritis (ON) in patients (pts) with aquaporin-4 (AQP4) antibody-positive (AQP4+) and myelin oligodendrocyte glycoprotein (MOG) antibody-positive (MOG+) neuromyelitis optica spectrum disorders (NMOSDs) led to optimal visual outcomes when administered within 4 days of onset compared with delayed onset.

Why this matters

  • ON in NMOSD pts is usually responsive to corticosteroid treatment, but visual outcomes in these pts have historically been poor.

  • Previous studies have shown that early corticosteroid treatment can impact visual outcomes, but these studies included few pts with NMOSD, and no MOG+ pts.

  • These findings suggest that treatment should be administered quickly in all forms of ON, even if serotype is unknown at presentation.

Mochten Sie mehr lesen?

Möchten Sie mehr lesen?

Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.

Sie haben bereits einen Account? Einloggen

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.